5 Best Up and Coming Pharmaceutical Stocks to Buy Now

2. Septerna, Inc. (NASDAQ:SEPN)

Number of Hedge Fund Holders: 31

Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list.

TheFly reported on June 11 that Guggenheim began coverage of SEPN with a Buy rating and assigned the company a $52 price target.

In another operational update, Septerna, Inc. (NASDAQ:SEPN) highlighted progress with SEP-479, announcing on June 8 that the first comprehensive preclinical characterization of the candidate had been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting (ENDO 2026). The presentation will focus on the pharmacological profile of SEP-479, a selective small-molecule PTH1R agonist being developed as a potential oral treatment for hypoparathyroidism. SEPN reported that preclinical studies demonstrated strong activity in both laboratory and animal models, supporting the candidate’s potential as an oral therapy.

SEP-479 is currently being evaluated in a Phase 1 trial involving healthy volunteers, with initial data expected in late 2026 or early 2027. The company stated that these findings further demonstrate the potential of its Native Complex Platform to develop oral small molecules targeting challenging GPCR pathways. SEPN believes SEP-479 could provide a once-daily oral approach designed to replace PTH activity and potentially improve treatment options for patients with hypoparathyroidism.

Septerna, Inc. (NASDAQ:SEPN) is a clinical-stage biotech company developing oral small-molecule drugs targeting GPCRs to treat endocrine, immune, inflammatory, and metabolic diseases.